SCHEMBL13745604

SCHEMBL13745604

Cc1ccc(/C=C/C(=O)CC(=O)CCc2ccc(O)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.59
AKR1B1 P15121 2/20 0.59
AKR1B10 O60218 1/20 0.59
PTGS2 P35354 1/20 0.59
GLO1 Q04760 1/20 0.59
CAMK2A Q9UQM7 1/20 0.59
BACE1 P56817 11/20 0.58
RAB9A P51151 2/20 0.51
MAOA P21397 2/20 0.51
KMT2A Q03164 1/20 0.51
POLB P06746 1/20 0.51
MAPT P10636 1/20 0.51
MMP1 P03956 1/20 0.51
MMP2 P08253 1/20 0.51
MMP9 P14780 1/20 0.51
AKR1C3 P42330 1/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
MET P08581 1/20 0.48
CA4 P22748 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1573468 0.93 AKR1B10 (0.69) MAOBAKR1B1AKR1B10PTGS2GLO1
SCHEMBL1573466 0.93 AKR1B10 (0.69) MAOBAKR1B1AKR1B10PTGS2GLO1
SCHEMBL13746120 0.86 BACE1 (0.61) MAOBAKR1B1AKR1B10PTGS2GLO1
SCHEMBL13311577 0.86 GSK3B (0.65) MAOBAKR1B1AKR1B10PTGS2GLO1
SCHEMBL10005951 0.85 MAOB (0.81) MAOBAKR1B1AKR1B10PTGS2GLO1
SCHEMBL21778869 0.82 RAB9A (0.68) MAOBRAB9AMAOAKMT2APOLB
SCHEMBL21998520 0.81 AKR1B10 (0.67) MAOBAKR1B1AKR1B10PTGS2GLO1
SCHEMBL3204597 0.80 BACE1 (0.74) MAOBAKR1B1AKR1B10PTGS2GLO1
SCHEMBL3204616 0.80 BACE1 (0.74) MAOBAKR1B1AKR1B10PTGS2GLO1
SCHEMBL17019815 0.79 ABCB1 (0.76) MAOBAKR1B1PTGS2GLO1CAMK2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572829-B2 Pharmaceutical compositions useful in prevention and treatment of Beta-amyloid protein-induced disease KIM DARRICK S H L 2009-08-11 US disclosed
US-20080085932-A1 Pharmaceutical Compositions Useful In Prevention and Treatment of Beta-Amyloid Protein-Induced Disease KIM DARRICK S 2008-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085932-A1 Pharmaceutical Compositions Useful In Prevention and Treatment of Beta-Amyloid Protein-Induced Disease APP, BACE1, PSEN1 MAOB 1147/4885AKR1B1 1916/4885AKR1B10 1329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.